Navigation Links
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Date:12/8/2007

ed the injectable suspension formulation and 13 received the Cremophor-containing formulation.

To date, the response rate at the 340 mg/m2 dose is lower than that in the earlier, dose-escalating group that received doses of tanespimycin between 100 and 275 mg/m2.

The combination of tanespimycin and bortezomib was well-tolerated. There was no increase in toxicity with the injectable suspension formulation compared to the Cremophor-containing formulation observed with the tanespimycin plus bortezomib combination dosed at 340 mg/m2 and 1.3 mg/m2, respectively. Common toxicities were similar for the two tanespimycin formulations. Common tanespimycin toxicities (primarily Grade 1-2) were gastrointestinal (diarrhea, nausea, vomiting), fatigue, reversible increased liver function tests (LFT), dizziness, headache, insomnia and musculoskeletal malaise. Grade 3 tanespimycin toxicities were limited to diarrhea, fatigue and increased LFT. No cardiovascular toxicity was observed.

Common toxicities associated with bortezomib included thrombocytopenia (Grade 3-4 at 1.3 mg/m2) and neuropathy (Grade 1-2, at 1.3 mg/m2). A lower than anticipated rate of neuropathy was observed in the tanespimycin plus bortezomib combination, and no patient experienced a Grade 3 neuropathy. In prior bortezomib trials (the SUMMIT and CREST trials), 13% Grade 3 neuropathy was observed. This observation supports the hypothesis that treatment with tanespimycin exerts a neuroprotective effect.

Tanespimycin in Myeloma Evaluation (TIME) Program

The Phase 1b trial is ongoing and multiple patients remain on study. Kosan intends to complete the trial and report the final data at a later date.

Kosan's TIME registration program has been opened, with the initiation of the TIME-2 trial. TIME-2 is a Phase 2/3 trial in patients with relapsed- refractory multiple myeloma. The multi-site, open-label trial is being conducted primarily in the US and Europe. TIME-2 is designed to c
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... With advancements in neurological and functional ... seeing new growth, according to Kalorama Information. Though ... the majority of market volume, newer 3T systems ... are creating opportunities for more sophisticated applications. The medical ... a rate of 4%, with world market revenues ...
(Date:12/17/2014)... Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... and Trademark Office (USPTO) has issued a key ... cell-based immunotherapeutic vaccine targeting six tumor antigens that ... US Patent No. 8,871,211, which issued October 28, ... administering a dendritic cell composition comprising peptide epitopes ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... AUGUSTINE, Fla., Aug. 10, 2011 Flagler Hospital ... selected the Sunrise Enterprise ™ suite of clinical ...  In addition to implementing Sunrise within the hospital, Flagler ... Record (EHR) and practice management solution for its ...
... Simbionix USA Corporation, the world,s leading provider of ... and the healthcare industry, is pleased to announce it ... its innovative PROcedure Rehearsal Studio ™ . ... in industry product, allowing clinicians to create patient specific 3D ...
Cached Medicine Technology:Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 2Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 3Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 4Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 5Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 6Patent Granted for Simbionix Procedure Rehearsal Studio™ 2
(Date:12/21/2014)... 2014 The Oncology Institute of Hope and ... Ana and Whittier offices. The Hope for the Holidays Toy ... patients and their families during the holiday season. This year, ... 70 children between both offices. This event continues to be ... community service team, store managers and assistant managers came out ...
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just done ... drastically cut prices to all its prom dresses already, ... 2015. Many of the hottest styles are sold here ... and more. , A spokesman for MissyDress says, “The ... princess prom dresses or sweetheart chiffon prom dresses, you ...
(Date:12/20/2014)... DePuy Pinnacle hip lawsuits ( ... the artificial hip system was defectively designed continue ... Bernstein Liebhard LLP reports. According to an Order ... on December 2nd, counsel in 10 DePuy Pinnacle ... on November 19, 2014, with depositions to conclude ...
(Date:12/20/2014)... Doctor’s Office Urgent Care of Paramus, New Jersey has served ... They’ve treated over 40,000 patients while carrying out their mission ... the Paramus area. , For 2015, the practice is ... top-notch board certified physicians: Christine Milosis MD, Sandra Ugras Rey ... will work tirelessly to carry out The Doctor’s Office ...
(Date:12/20/2014)... The aftermath of the November 24th hack ... only in Hollywood, but worldwide. As reported in ... of that attack are starting a finger-pointing game which could ... But they are not the only ones affected, regular employees ... some embarrassing times ahead, agents and lawyers could be in ...
Breaking Medicine News(10 mins):Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5
... 30, PharmAthene, Inc. (NYSE Amex: PIP ... and chemical threats, today reported operational and financial results ... years ended December 31, 2008 and 2007, the Company ... Revenues for the full year 2008 consisted primarily ...
... new studying appearing in Congenital Heart Disease ... and women who underwent surgery for congenital heart disease ... produced evidence that shows how medicine may provide preconditions ... life. , In recent decades, survival rates and the ...
... for fiscal fitness.DOVER, N.H., March 30 No more excuses! Planet ... during these tough economic times. From April 1 - April ... members will pay a one-dollar sign-up fee and ... All are encouraged to register either online at ...
... chemicals used to make bombs can foil detection because ... detection techniques. Tel Aviv University has developed the ultimate ... "hidden" molecules into something we can detect and see. ... Shabat of TAU,s Raymond and Beverly Sackler School of ...
... Newsletter for Healthcare ProfessionalsVOORHEES, N.J., March 30 ... urticaria (hives) and angioedema can be challenging, ... a number of immunologic and nonimmunologic mechanisms. ... seemingly identical presentation of angioedema subtypes. It ...
... check-in, ,self-room, access medical information and learn about ... new portable terminal used by patients during hospital, ... and streamline patient check-in, plus provides doctors, nurses ... enhancing tool. International Medical Solutions has introduced ...
Cached Medicine News:Health News:PharmAthene Reports Year End 2008 Financial Results 2Health News:PharmAthene Reports Year End 2008 Financial Results 3Health News:PharmAthene Reports Year End 2008 Financial Results 4Health News:PharmAthene Reports Year End 2008 Financial Results 5Health News:PharmAthene Reports Year End 2008 Financial Results 6Health News:PharmAthene Reports Year End 2008 Financial Results 7Health News:Study examines effect of heart surgery on employment 2Health News:A 'bionic nose' that knows 2Health News:New Directions in Angioedema: A Focus on Pathogenesis and Classification 2Health News:New Mobile Patient Communicator(TM) Gives Patients an Interactive Education Tool and Boosts Nurse Productivity 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: